Nasal Drug Delivery References 2016

1. Mygind N. Nasal Allergy. 2nd edition. Blackwell Scientific Publication, Oxford 1979.

2. Herzon FS. Nasal ciliary structural pathlogy. Laryngoscope 1983; 93:63-67.

3. Satir P, Sleigh MA. The physiology of cilia and mucociliary interactions. Ann. Rev. Physiol. 1990; 52:137-155.

4. Duchateau G, Graamans K, Zuidena J, Merkus FWHM. Correlation between nasal ciliary beat frequency and mucus transport rate in volunteers. Laryngoscope 1985; 95:854-859.

5. Liote H. Role of mucus and cilia in nasal mucociliary clearance in healthy subjects. Am. Rev. Respir. Dis. 1989; 140:132-136.

6. Becquemin MH. Particle deposition and resistance in the noses of aduls and children. Europ. Res. J. 1991; 4:694-701.

7. Proctor DF, Andersen I, Lundqvuist G. Clearance of inhaled particles from the human nose. Arch. Intern. Med. 1973; 131:132-139.

8. Quinlan MF, Salman SD, Swift DL, Wagner HN, Proctor DF. Measurement of mucociliary function in man. Am. Rev. Resp. Dis. 1969; 99:13-23.

9. Andersen I, Lundqvist GR, Proctor DF. Human nasal function under four controlled humidities. Am. Rev. Resp. Dis. 1972; 106:438-449.

10. Andersen I, Lundqvist GR, Proctor DF. Human nasal mucosal function in a controlled climate. Arch. Environ. Health 1971; 23:408-420.

11. Andersen I, Camner P, Jensen P, Philipson K, Proctor DF. A comparison of nasal and tracheobronchial clearance. Arch. Environ. Health 1974; 29:290-293.

12. Sakakura Y, Ukai R, Matima Y, Murai S, Harada T, Myoshi Y. Nasal mucociliary clearance under various conditions. Acta Otolaryngol. 1983; 96:167-173.

13. Bang BG, Mukherjee AL, Bang FB. Human nasal mucous flow rates. J. John Hopkins Med. 1967; 121:38-48.

14. Batts AH, Marriott C, Martin GP, Bond SW, Greaves JL, Wilson CG. The use of a radiolabeled saccharin solution to monitor the effect of the preservatives thiomersal, benzalkonium chloride and EDTA on human nasal clearance. J. Pharm. Pharmacol. 1991; 43:180-185.

15. Ridley D, Wilson CG, Washington N, Perkins AC, Wastie M, Ponchel G, et al. The effect of posture on the nasal clearance of starch microspheres. STP Pharma Sciences 1995; 5:442-446.

16. Puchelle E, Aug F, Pham QT, Bertand A. Comparison of three methods for measuring nasal mucociliary clearance in man. Acta Otolaryngol. 1981; 91:297-303.

17. Bond SW. Intranasal administration of drugs. In. Drug Delivery to the Respiratory Tract. Ganderton D. and Jones T.M. (eds) Ellis Horwood, Chicester 1987:133-139.

18. Armengot M, Basterra J, Marco J. Nasal mucociliary function during the menstrual cycle in healthy women. Rev. Laryngol. Otolaryngol. Rhinol. 1990; 111:107-109.

19. Hady MR, Shehata O, assan R. Nasal mucociliary function in different diseases of the nose. J. Laryngol. Otolaryngol. 1983; 97:497-501.

20. Suzumura E, Takeuchi K. Antigen reduces nasal transepithelial electric potential differences and alters ion transport in allergic rhinitis in vivo. Acta Otolaryngol. 1992; 112:552-558.

21. Awotedu AA, Babalola OO, Lavani EO, Hart PD. Abnormal mucociliary action in asthma and bronchiectasis. Afr. J. Med. Sci. 1990; 19:153-156.

22. Pederson H, Mygind N. Absence of axonemal arms in the nasal mucosa cilia in Kartagener's syndrome. Nature (London) 1976; 262:494-495.

23. Takeuchi K. Nasal mucociliary clearance in Sjörgren's syndrome. Dissociation in flow between sol and gel layers. Acta Otolaryngol. 1989; 108:126-129.

24. Lee SW, Hardy JG, Wilson CG, Smelt GJC. Nasal sprays and polyps. Nucl. Med. Commun. 1984; 5:697-703.

25. Andersen I, Lundqvist GR, Jensen PL, Proctor DF. Human response to controlled levels of sulphur dioxide. Arch. Environ. Health 1974; 28:31-39.

26. Stanley PJ, Wilson R, Greenstone MA, MacWilliam L, Cole PJ. Effect of cigarette smoking on nasal mucociliary clearance and ciliary beat frequency. Thorax 1986; 41:519-523.

27. Ewert G. On the mucus flow in the human nose. Acta Otolaryngol. 1965; Suppl. 200:162.

28. Aoki FK, Crowley JCW. Distribution and removal of human serum albumin-technetium 99m instilled intranasally. Br. J. Clin. Pharmacol. 1976; 3:869-878.

29. Proctor DF. Nasal mucus transport and our ambient air. Laryngoscope 1983; 93:58-62.

30. Torjussen W, Solberg A. Histological findings in the nasal mucosa of nickel workers. Acta Otolaryngol. 1976; 82:132-134.

31. Acheson ED, Cowdell RH, Hadfield E, Macbeth RG. Nasal cancer in woodworkers in the furniture industry. Br. Med. J. 1968; 2:587-596.

32. Andersen HC, Solgaard J, Andersen I. Nasal cancer and nasal mucus transport in woodworkers. Acta Otolarnygol. 1976; 52:263-265.

33. Dalhamn T. Mucus flow and ciliary activity in the trachea of healthy rats and rats exposed to respiratory irritant gases. Acta Physiol. Scand. 1956; 36 Suppl. 123:1-15.

34. Sakethoo K, Yergin BM, Januskiewicz A, Kovitz K, Sackner MA. The effect of nasal decongestants on nasal mucus velocity. Am. Rev. Resp. Dis. 1978; 118:251-254.

35. Borum P, Olsen L, Winther B, Mygind N. Ipratropium nasal spray: a new treatment for rhinorrhea in the common cold. Am. Rev. Respir. Dis. 1981; 123:418-420.

36. Norman PS, Naclerio RM, Creticos PM, Togas A Lichtenstein LM, Mediator relase after allergic and physical nasal challenge. Int. Arch. Allergy Appl. Immunol. 1985; 77:57-63.

37. Chien YW, Su KSE, Chang S. Nasal systemic drug delivery, in Drugs and the pharmaceutical sciences. Chien, Y.W. (ed) Marcel Dekker, New York 1989:1-26.

38. Richardson DW, Robinson AG. Desmopressin. Ann. Int. Med. 1985; 103:228-239.

39. Hilsted J, Madasbad S, Hvidberg A. Intranasal insulin therapy: the clinical realities. Diabetologica 1995; 38:680-684.

40. Lee WA, Ennis RD, Longenecker JP, Bengtsson P. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharm. Res. 1994; 11:747-750.

41. Bryant ML, Brown P, Gurevich N, McDougall IR. Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine. Nucl. Med. Commun. 1999; 20:171-174.

42. Merkus FWHM, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PHM, Hermens WAJJ, et al. Cyclodextrins in nasal drug delivery. Adv. Drug Deliv. Rev. 1999; 36:41-57.

43. Hermens WAJJ, Belder CWJ, Merkus JMWM, Hooymans PM, Verhoef J, Merkus FWHM. Intranasal estradiol administration to oophorectomized women. Europ. J. Obstet. Gynecol. Reprod. Biol. 1991; 40:35-41.

44. Merkus FWHM, Schipper NGM, Verhoef JC. The influence of absorption enhancers on the intranasal insulin absorption in normal and diabetic subjects. J. Cont. Rel. 1996; 41:69-75.

45. Heyder J, Rudolf G. Deposition of aerosol particles in the human nose. Inhaled Part. 1975; 4:107-126.

46. Batts Lansley A. mucociliary clearance and drug delivery via the respiratory tract. Adv. Drug Deliv. Rev. 1993; 11:299-327.

47. Malmberg H, Holopainen E, Simola M, Böss I, Lindquist N. A comparison between intranasal budesonide dry powder in the treatment of hay fever symptoms. Rhinol. 1991; 29:137-141.

48. Washington N, McGlashan JA, Jackson SJ, Bush D, Pitt KG, Rawlins DA, Gill, D. The effect of nasal patency on the clearance of saline in healthy volunteers. Pharm. Res. 2000; In press.

49. Homer JJ, Raine CH. An endoscopic photographic comparison of nasal drug delivery by aqueous spray. Clin. Otolaryngol. 1998; 23:560-563.

50. Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect of F VIII/vWF, pharmacokinetics and reproducibility. Thromb. Haemostat. 1987; 58:1033-1036.

51. Anik ST, McRae G, Nerenberg C. Nasal absorption of nafarelin decapeptide [D-Nal(2)6] LHRH in rhesus monkey. J. Pharm. Sci. 1984; 73:684-685.

52. Newman SP, Steed KP, Hardy JG, Wilding IR, Hooper G, Sparrow RA. The distribution of anintranasal insulin formulation in healthy volunteers: Effect of different administration techniques . J. Pharm. Pharmacol. 1994; 46:657-660.

53. Harris AS, Svensson E, Wagner ZG, Lethagen D, Nilsson IM. Effect of viscosity on particle size, deposition and clearance of nasal delivery systems containing desmopressin. J. Pharm. Sci. 1988; 77:405-408.

54. Pennington AK, Ratcliffe JH, Wilson CG, Hardy JG. The influence of solution viscosity on nasal spray deposition and clearance. Int. J. Pharmaceut. 1988; 43:221-224.

55. Jackson SJ, Bush D, Washington N, Ron ES, Schiller M. Determination of the nasal retention of Smart hydrogel™ using gamma scintigraphy (abstract). J. Pharm. Pharmacol. (suppl. 4) 1997; 49:84.

56. Nagai T, Nishimoto Y, Nambu N, Suzuki Y, Sekine K. Powder dosage form for nasal administration. J. Cont. Rel. 1984; 1:15-22.

57. Pritchard K, Lansley AB, Martin GP, Halliwell M, Marriott C, Benedetti M. Evaluation of the bioadhesive properties of hyaluronan derivatives: detachment rate and mucociliary transport studies. Int. J. Pharmaceut. 1996; 129:137-145.

58. Edman P, Bjork E, Ryden L. Microspheres as a nasal delivery system for peptide drugs. J. Cont. Rel. 1992; 21:165-172.

59. Ilium L, Farraj NF, Fisher AN, Gill I, Miglietta M, Benedetti LM. Hyaluronic acid ester microspheres as a nasal delivery system for insulin. J. Cont. Rel. 1994; 29:133-141.

60. Genta I, Costantini M, Montanari L. Chitosan microspheres for nasal delivery: Effect of cross-linking agents on release characteristics. Proc. Cont. Rel. Soc. 1996; 23:377-378.

61. Marttin E, Schipper NGM, Verhoef JC, Merkus FWHM. Nasal mucociliary clearance as a factorin nasal drug delivery . Adv. Drug Deliv. Rev. 1998; 29:13-38.

62. Van de Donk HJM, Mercus FWHM. Nasal drops: do they damage ciliary movement? Pharm. Int. 1981; 2:157.

63. Bond SW, Hardy JG, Wilson CG. Deposition and clearance of nasal sprays. Proceedings of the 2nd Europ. Congr. Biopharmaceut. Pharmacokinet. 1983:93-97.

64. Berg OH, Lie K, Steinsvag SK. The effects of topical nasal steroids on rat respiratory mucosa in vivo, with special reference to benzalkonium chloride. Allergy 1997; 52:627632.

65. Dondeti P, Zia H, Needham TE. In vivo evaluation of spray formulations of human insulin for nasal delivery. International Journal of Pharmaceutics 1995; 122:91-105.

66. Braat JPM, Ainge G, Bowles JAK. The lack of effect of benzalkonium chloride on the cilia of the nasal mucosa in patients with perennial allergic rhinitis: a combined functional, light scanning and transmission electron microscopy study. Clin. Exp. Allergy 1995; 25:957-965.

67. Joki S, Saano V, Nuutinen J, Virta P, Karttunen P, Silvasti M, et al. Effects of some preservative agents on rat and guinea pig tracheal and human ciliary beat frequency. Am. J. Rhinol. 1996; 10:181-186.

68. Batts AH, Marriott C, Martin GP, Wood CF, Bond SW. The effect of some preservatives used in nasal preparations on the mucus and ciliary components on mucociliary clearance. J. Pharm. Pharmacol. 1990; 42:145-151.

69. Schipper NGM, Verhoef J, Romeijn SG, Merkus FWHM. Absorption enhancers in nasal insulin delivery and their influence on nasal ciliary functioning. J. Cont. Rel. 1992; 21:173-186.

70. Van de Donk HJM, Van Egmond ALM, Van den Huevel AGM, Zuidema J, Mercus FWHM. The effects of drugs on ciliary motility. I Decongestants. Int. J. Pharmaceut. 1982; 12:57-65.

71. Duchateau GSMJE. Studies on nasal drug delivery. Pharm. Weekblad 1987; 9:326-328.

72. Duchateau GSMJE, Zuidema J, Merkus FWHM. Bile salts and intranasal drug absorption. Int. J. Pharmaceut. 1986; 31:193-199.

73. Vinther B, Elbron D. Nasal mucociliary function during penicillin treatment. Acta Otolaryngol. 1978; 86:266-267.

74. Kimmerle R, Rolla AR. Iatrogenic Cushing's syndrome due to dexamethasone nasal drops. Am. J. Med. 1985; 79:535-537.

75. Su XY, Po ALW. The effect of some commercially available antihistamine and decongestant intra-nasal formulations on ciliary beat frequency. J. Clin. Pharm. Ther. 1993; 18:219-222.

76. Garay RP. Azalastaine: well known ciliotoxic agent? Int. J. Pharm. 1996; 136:181-183.

77. Hehar SS, Mason JD, Stephen AB, Washington N, Jones NS, Jackson SJ, Bush D. twenty four hour ambulatory nasal pH monitoring. Clin. Orolaryngol. Appl. Sci. 1999; 24:2425.

78. Gibson RE, Olanoff LS. Physicochemical determinants of nasal drug absorption. J. Cont. Rel. 1987; 6:361-366.

79. Morimoto K, Yamaguchi H, Iwakura Y, Morisaka K, Ohashi Y, Nakai Y. Effects of viscous hyaluronate-sodium solutions on the nasal absorption of vasopressin and an analogue. Pharmaceut. Res. 1991; 8:471-474.

80. Su XY, Po ALW. Surface-response study of the effect of pH and tonicity on ciliary activity. S.T.P. Pharma Sciences 1994; 4:82-85.

81. Hirai S, Ikenaga R, Matsuzawa T. Nasal absorption of insulin in dogs. Diabetes 1978; 27:269-299.

82. Washington N, Steele RJC, Jackson SJ, Bush D, Mason J, Gill DA, Pitt K, Rawlind DA.. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int. J. Pharmaceut. In press.

83. Gizurarson S. The relevance of nasal physiology to the design of drug absorption studies. Adv. Drug Deliv. Rev. 1993; 11:329-347.

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment